Verition Fund Management LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Verition Fund Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $2.8 Million - $3.08 Million	71,985 Added 54.2%	204,808 $8.37 Million
Q1 2024 May 14, 2024	BUY	$40.88 - $43.27 $2.16 Million - $2.29 Million	52,823 Added 66.03%	132,823 $5.61 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $1.62 Million - $3.4 Million	80,000 New	80,000 $3.39 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $496,153 - $805,908	19,457 New	19,457 $550,000
Q2 2022 Aug 15, 2022	SELL	$20.62 - $37.15 $1.69 Million - $3.05 Million	-82,135 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$23.5 - $35.38 $1.93 Million - $2.91 Million	82,135 New	82,135 $2.88 Million
Q3 2021 Nov 15, 2021	SELL	$21.26 - $38.85 $797,845 - $1.46 Million	-37,528 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$12.56 - $29.69 $2.81 Million - $6.65 Million	-223,976 Reduced 85.65%	37,528 $961,000
Q1 2021 May 18, 2021	BUY	$12.37 - $17.74 $2.8 Million - $4.01 Million	226,074 Added 638.09%	261,504 $3.59 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $347,922 - $647,306	35,430 New	35,430 $587,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.